199 related articles for article (PubMed ID: 19018258)
1. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
2. ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.
Jerjees DA; Alabdullah M; Alkaabi M; Abduljabbar R; Muftah A; Nolan C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Aug; 147(1):25-37. PubMed ID: 25085753
[TBL] [Abstract][Full Text] [Related]
3. Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Morgan L; Gee J; Pumford S; Farrow L; Finlay P; Robertson J; Ellis I; Kawakatsu H; Nicholson R; Hiscox S
Cancer Biol Ther; 2009 Aug; 8(16):1550-8. PubMed ID: 19830888
[TBL] [Abstract][Full Text] [Related]
4. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Elsberger B; Paravasthu DM; Tovey SM; Edwards J
J Cancer Res Clin Oncol; 2012 Feb; 138(2):327-32. PubMed ID: 22134837
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
6. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
7. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
8. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
9. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
10. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
11. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Elsberger B; Tan BA; Mitchell TJ; Brown SB; Mallon EA; Tovey SM; Cooke TG; Brunton VG; Edwards J
Am J Pathol; 2009 Oct; 175(4):1389-97. PubMed ID: 19762712
[TBL] [Abstract][Full Text] [Related]
12. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
[TBL] [Abstract][Full Text] [Related]
13. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
14. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
Myers E; Fleming FJ; Crotty TB; Kelly G; McDermott EW; O'higgins NJ; Hill AD; Young LS
Br J Cancer; 2004 Nov; 91(9):1687-93. PubMed ID: 15477868
[TBL] [Abstract][Full Text] [Related]
15. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
16. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F; Milella M; Melucci E; Di Benedetto A; Sperduti I; Perrone-Donnorso R; Perracchio L; Venturo I; Nisticò C; Fabi A; Buglioni S; Natali PG; Mottolese M
Breast Cancer Res; 2008; 10(5):R74. PubMed ID: 18771580
[TBL] [Abstract][Full Text] [Related]
17. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Rexhepaj E; Brennan DJ; Holloway P; Kay EW; McCann AH; Landberg G; Duffy MJ; Jirstrom K; Gallagher WM
Breast Cancer Res; 2008; 10(5):R89. PubMed ID: 18947395
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
20. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
